J&J expanding vaccine trial to adolescents
Johnson & Johnson will soon start testing its COVID-19 vaccine candidate in U.S. adolescents, the company announced Friday. The company plans to begin testing the vaccine in a small number of 16 and 17 year olds as part of an ongoing Phase 2 trial for adults, gradually expanding the trial to children aged 12-17 after reviewing the initial data.
It is currently enrolling adolescents in Spain and the United Kingdom and expects to start enrolling them soon in the U.S., Netherlands and Canada, followed by Brazil and Argentina.
In February, the U.S. Food and Drug Administration authorized emergency use of the vaccine for individuals 18 and older.
Related News Articles
Headline
The Senate Finance Committee Feb. 4 voted 14-13 to advance Robert F. Kennedy Jr.’s nomination for secretary of the Department of Health and Human Services. A…
Headline
Respiratory illness activity remains high across the country, according to the latest data from the Centers for Disease Control and Prevention. Seasonal flu…
Headline
The Occupational Safety and Health Administration Jan. 13 announced that it terminated efforts to establish a final COVID-19 safety standard to protect workers…
Headline
The Department of Health and Human Services Dec. 10 amended the Public Readiness and Emergency Preparedness Act declaration for COVID-19, extending liability…
Headline
AHA's latest social media toolkit for encouraging vaccination against the flu and COVID-19 provides fall-themed social media posts and graphics. Download the…
Headline
The Centers for Disease Control and Prevention last week endorsed a recommendation for people aged 65 and older and for immunocompromised individuals to…